Silo Pharma files 8-K with material agreement and unregistered sales

An 8-K 1.01 filing signals a material agreement that could affect revenue, partnerships, or financial position; Item 3.02 suggests unregistered securities sales, indicating potential dilution or funding needs. Without full details, direction is unclear but the dual-item disclosure warrants attention as these are not routine filings.

Silo Pharma announced it signed a significant deal and sold securities (likely shares or warrants) to raise money. Both moves matter to investors since they could affect the company's value and direction.